Impact of Common Medications on Serum Total Prostate-specific Antigen Levels and Risk Group Assignment in Patients with Prostate Cancer

Anticancer Research, 05/31/2011

Nieder C et al.– Compared to the U.S.A. National Comprehensive Cancer Network risk group assignment based on measured Prostate–specific Antigen (PSA) level, reassignment after correcting for medication use resulted in changes among patients with low or intermediate risk. No such changes can be expected in patients belonging to the high–risk group. These results support the concerns expressed previously, given that risk group assignment, which may be inaccurate in patients using concomitant medications, eventually guides choice of treatment.

Print Article Summary Cat 2 CME Report